They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.
It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention. Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Since then, Sanford C. Bernstein, Raymond James, Stifel Nicolaus, and Barclays have all raised their price targets on the healthcare conglomerate.
Abbott Laboratories ( NYSE:ABT ) Full Year 2022 Results Key Financial Results Revenue: US$43.7b (up 1.3% from FY 2021...